Corrigendum to "Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis" [Crit. Rev. Oncol./Hematol. 201 (2024) 104416]

Affiliations

¹ Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain; Department of Medical Oncology, Taunton and Somerset NHS Foundation Trust, Taunton, United Kingdom. Electronic address: Joelveas@gmail.com.
² Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain.
³ Department of Basic Medical Sciences, University of Lleida, IRBLLEIDA, Lleida, Spain.
⁴ Department of Radiation Oncology, Arnau de Vilanova University Hospital, Lleida, Spain.
⁵ Department of Medical Oncology, Vall d' Hebron University Hospital, Barcelona, Spain.

Published Erratum

Joel Veas Rodríguez et al. Crit Rev Oncol Hematol. 2024 Oct.

. 2024 Oct:202:104466.

doi: 10.1016/j.critrevonc.2024.104466. Epub 2024 Aug 10.

¹ Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain; Department of Medical Oncology, Taunton and Somerset NHS Foundation Trust, Taunton, United Kingdom. Electronic address: Joelveas@gmail.com.
² Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain.
³ Department of Basic Medical Sciences, University of Lleida, IRBLLEIDA, Lleida, Spain.
⁴ Department of Radiation Oncology, Arnau de Vilanova University Hospital, Lleida, Spain.
⁵ Department of Medical Oncology, Vall d' Hebron University Hospital, Barcelona, Spain.

No abstract available

Erratum for

Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis.
Veas Rodríguez J, Prieto A, Vilaprinyo E, Bonet M, Diez M, Salud A, Montal R. Veas Rodríguez J, et al. Crit Rev Oncol Hematol. 2024 Sep;201:104416. doi: 10.1016/j.critrevonc.2024.104416. Epub 2024 Jun 12. Crit Rev Oncol Hematol. 2024. PMID: 38871262